📰 Priority Review News
Page 58 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
May 17, 2023
/PRNewswire/ -- BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of results from a simulation study evaluating...
May 17, 2023
Stockholm, May 17, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of results from a simulation study evaluating the
May 17, 2023
The FDA has accepted for Priority Review the BLA for TAK-755 for the treatment of congenital thrombotic thrombocytopenic purpura.
May 16, 2023
TOKYO and CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts
May 16, 2023
16.05.2023 - TOKYO and CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, Eisai) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, Biogen) ... Seite 1
May 16, 2023
TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the
May 16, 2023
WESTON (dpa-AFX) - Eisai Co., Ltd. and Biogen Inc. (BIIB) said that Health Canada has accepted a New Drug Submission or NDS for lecanemab (brand name in the U.S.: LEQEMBI), an investigational anti-amyloid
May 16, 2023
(RTTNews) - Eisai Co., Ltd. and Biogen Inc. (BIIB) said that Health Canada has accepted a New Drug Submission or NDS for lecanemab (brand name in ...
May 16, 2023
STOCKHOLM, May 16, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...
May 16, 2023
STOCKHOLM, May 16, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab